ASCO 2021 - Metastatic or recurrent cancer of the uterine cervix Encouraging results with second generation immunotherapy

ASCO 2021

Metastatic or recurrent cancer of the uterine cervix: Encouraging results with second generation immunotherapy

An early trial presented by the Institut Bergonié and Gustave Roussy at the 2021 ASCO Conference shows that patients with metastatic or recurrent cancer of the cervix may benefit from dual immunotherapy. The new generation agent, Simlukafusp Alfa, a variant of interleukin-2, shows promising signs of efficacy by doubling the response to anti-PD-L1 immunotherapy alone, without causing major adverse effects.

Good to know 08

Newsletter Good to Know : l'actualité scientifique en cancérologie, vue par Gustave Roussy.

Parrainer l’équipe de chercheurs contre les sarcomes

Les professionnels de la recherche clinique

Les professionnels de la recherche clinique : plus de 20 métiers différents interagissent pour conduire un essai clinique au bénéfice du patient.

Pages